UK markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.76+0.32 (+1.83%)
At close: 04:00PM EDT
17.96 +0.20 (+1.13%)
After hours: 05:11PM EDT

Exelixis, Inc.

1851 Harbor Bay Parkway
Alameda, CA 94502
United States
650 837 7000

Full-time employees954

Key executives

NameTitlePayExercisedYear born
Dr. Stelios Papadopoulos Ph.D.Co-Founder & Independent Chair of the Board98kN/A1948
Dr. Michael M. Morrissey Ph.D.CEO, Pres & Director2.37M1.05M1961
Mr. Christopher J. SennerExec. VP & CFO1.09M2.14M1968
Dr. Peter Lamb Ph.D.Exec. VP of Scientific Strategy & Chief Scientific Officer909.46k10.72M1961
Mr. Jeffrey J. Hessekiel J.D.Exec. VP, Gen. Counsel & Sec.957.2k770.4k1969
Mr. Patrick J. Haley M.B.A., MBAExec. VP of Commercial846.43k466.38k1976
Dr. Dana T. Aftab Ph.D.Exec. VP of Bus. OperationsN/AN/AN/A
Ms. Susan T. HubbardExec. VP of Public Affairs & Investor RelationsN/AN/AN/A
Mr. Gregg BernierVP of MarketingN/AN/AN/A
Ms. Laura DillardExec. VP of HRN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Corporate governance

Exelixis, Inc.’s ISS governance QualityScore as of 1 May 2022 is 3. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 4; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.